Strides Pharma Science Ltd has reported a consolidated net loss of Rs 163.4 crore in the first quarter ended in June 2022, compensated by higher revenue. The company reported a consolidated net loss of Rs 244.1 crore for the same quarter a year ago. Revenue from operations stood at Rs 940.07 crore compared to Rs 688.37 crore in the year-ago period, marking a growth of 36.6 per cent.

• NHAI Shifts Highway Monetisation Towards InvITs in FY27
• Paradeep Parivahan Jumps to Rs 315 on JSW Electric Truck Deal
• How to Build a Diversified Investment Portfolio with Mutual Funds
• Biocon Touches Rs 325.50 on Yesintek Entry in Nine Markets
• Key Factors Behind Today’s Market Movement

The company reported that its revenues from Other Regulated Markets (ORM) were at Rs 304.7 crore in the first quarter of FY23, compared to Rs 223.2 crore in the corresponding fiscal period. Higher costs remain a cause of concern, and the company is focused on cost controls and manufacturing network optimization.